Phase II Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck
Categories (click each to see list of all clinical trials associated with that category): Head and Neck
Current Status: Open to accrual
Phase: II
Principal Investigator: Ganti, Apar
Contact Information:
Shannon Pivovar, RN
402-559-8711
shannon.pivovar@unmc.edu
Eligibility: https://clinicaltrials.gov/ct2/show/NCT02524275#eligibility
Summary
PRIMARY OBJECTIVES:
I. To evaluate in a phase II study the efficacy (the radiographic assessment of disease status after 2 cycles of therapy) of a combination of docetaxel and capecitabine in subjects with advanced squamous cell carcinoma of the head and neck who are not candidates for surgery or radiation therapy.
II. To evaluate the safety and toxicities of docetaxel and capecitabine in subjects with advanced squamous cell carcinoma of the head and neck.
III. To descriptively examine the effects of the combination of docetaxel and capecitabine on the quality of life of subjects with advanced squamous cell carcinoma of the head and neck.